Johnson & Johnson (JNJ) NYSEJohnson & Johnson begin human trials for Coronavirus vaccine as early as July. Alex Gorsky, CEO of Johnson & Johnson announced Wednesday June 10, 2020.

Johnson & Johnson’s seventh Chairman and CEO started his career at the company in 1988 as a sales representative. And that’s just one great fact about Alex Gorsky, whose exceptional leadership skills have helped make Johnson & Johnson a worldwide leader in healthcare. Source: Click Here

Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson, said, “Based on the strength of the preclinical data we have seen so far and interactions with the regulatory authorities, we have been able to further accelerate the clinical development of our investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant. Simultaneously, we are continuing our efforts to build important global partnerships and invest in our vaccine production technology and manufacturing capabilities. Our goal is to ensure we can deliver a vaccine to the world and protect people everywhere from this pandemic.”

The randomized, double-blind, placebo-controlled Phase 1/2a study will evaluate the safety, reactogenicity (response to vaccination), and immunogenicity (immune response) of the investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant  in 1045 healthy adults aged 18 to 55 years, as well as adults aged 65 years and older. The study will take place in the U.S. and  Belgium.

The Company is in discussions with the National Institutes of Allergy and Infectious Diseases with the objective to start the Phase 3 SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant, clinical trial ahead of its original schedule, pending outcome of phase 1 studies and approval of regulators.

[object HTMLElement]

Top 5  Institutional Holders

Holder   Shares   Date Reported   % Out       Value

Vanguard Group, Inc. (The)                   233,816,138               Mar 30, 2020           8.87%       30,660,310,175

Blackrock Inc.         192,545,915               Mar 30, 2020           7.31%       25,248,545,833

State Street Corporation                             151,549,024               Mar 30, 2020           5.75%       19,872,623,517

Geode Capital Management, LLC                             38,965,156                     Mar 30, 2020           1.48%       5,109,500,906

State Farm Mutual Automobile Insurance Co             34,574,792                     Mar 30, 2020           1.31%       4,533,792,474

Top Mutual Fund Holders

Holder   Shares   Date Reported   % Out       Value

Vanguard Total Stock Market Index Fund                           74,147,917                     Dec 30, 2019             2.81%       10,815,956,652

Vanguard 500 Index Fund                       52,581,325                     Dec 30, 2019             2.00%       7,670,037,877

SPDR S&P 500 ETF Trust 30,376,922                     Jan 30, 2020               1.15%       4,522,212,378

Vanguard Institutional Index Fund-Institutional Index Fund                     23,801,101                     Dec 30, 2019             0.90%                               3,471,866,602

Fidelity 500 Index Fund 23,219,414                     Jan 30, 2020               0.88%       3,456,674,162

CWEB has issued a Buy Rating for  Johnson & Johnson (JNJ) NYSEJohnson & Johnson and Price target of $200

CWEB.com is not registered as an investment adviser with the U.S. Securities and Exchange Commission. Rather, CWEB.com relies upon the “publisher’s exclusion” from the definition of investment adviser as provided under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws.